We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought... Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Show more
Ionis to hold first quarter 2024 financial results webcast PR Newswire CARLSBAD, Calif., April 23, 2024 Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif., April 23...
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire CARLSBAD, Calif., April 7, 2024 – Olezarsen met the primary...
Ionis to present at upcoming investor conferences PR Newswire CARLSBAD, Calif., April 1, 2024 CARLSBAD, Calif., April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today...
Ionis to hold olezarsen Phase 3 data webcast PR Newswire CARLSBAD, Calif., March 28, 2024 Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif., March 28, 2024...
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire CARLSBAD, Calif., March 25, 2024 – ...
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH PR Newswire CARLSBAD, Calif., March 13...
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.21 | 0.504443910641 | 41.63 | 42.25 | 40.385 | 957858 | 41.01315439 | CS |
4 | -2.51 | -5.6595264938 | 44.35 | 44.95 | 40.385 | 966805 | 42.56178114 | CS |
12 | -9.88 | -19.1028615623 | 51.72 | 52.49 | 40.385 | 1095355 | 44.77029628 | CS |
26 | -4.67 | -10.0408514298 | 46.51 | 54.4446 | 40.385 | 1120805 | 47.40485154 | CS |
52 | 4.77 | 12.8675478824 | 37.07 | 54.4446 | 34.32 | 1131563 | 44.3616096 | CS |
156 | -0.77 | -1.80708753814 | 42.61 | 54.4446 | 25.04 | 1117042 | 39.61042551 | CS |
260 | -31.07 | -42.6141818681 | 72.91 | 75.14 | 25.04 | 1084693 | 46.27197252 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions